Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20140783 | 0.88 | L3MBTL1 (0.63) | ELANEL3MBTL1PTGDR2KAT2BAPP | |
| SCHEMBL20140374 | 0.87 | L3MBTL1 (0.49) | ELANEL3MBTL1PTGDR2KAT2BAPP | |
| SCHEMBL9925005 | 0.86 | L3MBTL1 (0.49) | ELANEL3MBTL1PTGDR2POLBGAA | |
| SCHEMBL20139756 | 0.86 | L3MBTL1 (0.51) | ELANEL3MBTL1PTGDR2APPSNCA | |
| SCHEMBL20140434 | 0.82 | L3MBTL1 (0.46) | ELANEL3MBTL1APPSNCARET | |
| SCHEMBL20140277 | 0.82 | ELANE (0.46) | ELANEL3MBTL1PTGDR2APPSNCA | |
| SCHEMBL9925305 | 0.80 | ELANE (0.50) | ELANEL3MBTL1PTGDR2RET | |
| SCHEMBL10063592 | 0.80 | ELANE (0.47) | ELANEL3MBTL1PTGDR2APPSNCA | |
| SCHEMBL2883465 | 0.79 | MAPT (0.51) | ELANEL3MBTL1MEN1KMT2A | |
| SCHEMBL6068638 | 0.78 | MAPT (0.47) | ELANEL3MBTL1RXFP1PTGDR2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| US-11180493-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200071318-A1 | SGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2020-03-05 | — | — | US | disclosed |
| EP-3538520-A2 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071318-A1 | SGC STIMULATORS | GUCY1A2, GMPS, PDE2A | ELANE 2411/4885L3MBTL1 4698/4885RXFP1 903/4885 |
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | ELANE 2419/4885L3MBTL1 4695/4885RXFP1 870/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | ELANE 2419/4885L3MBTL1 4695/4885RXFP1 870/4885 |
| US-11180493-B2 | SGC stimulators | GUCY1A2, GMPS, PDE2A | ELANE 2411/4885L3MBTL1 4698/4885RXFP1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.